JAK2 encodes a non-receptor tyrosine kinase, which has been implicated in signaling by members of the type II cytokine receptor family to regulate cell proliferation, differentiation as well as apoptosis. The discovery of an acquired mutation in JAK2, termed JAK2 V617F, provided a unique opportunity for the re-evaluation of the diagnostic criteria describing BCR-ABL-negative myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
As the presence of the V617F mutation has been demonstrated in more than 95% of patients with PV and over 50% of those with ET and PMF, the JAK2 qPCR Assay is a powerful tool for MPN diagnoses and risk stratification to help optimize management.
With this new CE-IVD marking, DiagCor now offers CE-IVD precision oncology tests for KRAS/BRAF and JAK2. Additionally, the GenoQuestTM C-Kit qPCR Kit targets the D816V mutation, which has been implicated in the pathogenesis of several diseases including systemic mastocytosis (SM), gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML).
Headquartered in Hong Kong, DiagCor has been dedicated solely to molecular diagnostics (MDx) since 2006. The global leader in flow-through hybridization technology, the company offers a range of products, solutions and services related to RNA and DNA analysis. As well as providing MDx laboratory services to Asia Pacific practitioners, Diagcor develops and manufactures MDx products and solutions, and offers MDx medical translation services and MDx consulting.
DiagCor Life Science